Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN2 | P17706 | 9/20 | 0.55 |
| ▸ | PTPN1 | P18031 | 9/20 | 0.55 |
| ▸ | PTPN5 | P54829 | 8/20 | 0.55 |
| ▸ | ACLY | P53396 | 1/20 | 0.54 |
| ▸ | FBP1 | P09467 | 4/20 | 0.53 |
| ▸ | HSPD1 | P10809 | 1/20 | 0.51 |
| ▸ | HSPE1 | P61604 | 1/20 | 0.51 |
| ▸ | EDNRA | P25101 | 2/20 | 0.49 |
| ▸ | ITGA1 | P56199 | 1/20 | 0.49 |
| ▸ | PPARG | P37231 | 2/20 | 0.48 |
| ▸ | BRD4 | O60885 | 1/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.47 |
| ▸ | EDNRB | P24530 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4883514 | 0.91 | FBP1 (0.53) | FBP1EDNRAITGA1PPARGCYP3A4 | |
| SCHEMBL616005 | 0.91 | FBP1 (0.65) | PTPN2PTPN1PTPN5ACLYFBP1 | |
| SCHEMBL27422029 | 0.83 | MEN1 (0.56) | PTPN2PTPN1PTPN5ACLYFBP1 | |
| SCHEMBL618236 | 0.82 | PTPN1 (0.59) | PTPN2PTPN1PTPN5ACLYHSPD1 | |
| SCHEMBL617755 | 0.81 | FBP1 (0.65) | FBP1EDNRAEDNRB | |
| SCHEMBL8859238 | 0.76 | RAB9A (0.56) | PTPN2PTPN1PTPN5HSPD1HSPE1 | |
| SCHEMBL4875632 | 0.76 | LMNA (0.64) | ITGA1PPARG | |
| SCHEMBL28614348 | 0.76 | BRD4 (0.73) | PTPN2PTPN1PTPN5HSPD1HSPE1 | |
| SCHEMBL618899 | 0.75 | NPC1 (0.54) | EDNRAITGA1PPARGCYP3A4 | |
| Iodide SCHEMBL10395553 | 0.75 | RAB9A (0.55) | PTPN2PTPN1PTPN5HSPD1HSPE1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080255169-A1 | 4'-Fluoro-biphenyl-3-sulfonic acid benzo[1,3]dioxol-5-ylamide, for example; for use as an alpha 2 beta 1 integrin I domain inhibitor; use as a medicament for treating thrombosis and cancer spread | BIOTIE THERAPIES CORPORATION (FI) | 2008-10-16 | — | — | US | disclosed |
| EP-1732884-A1 | SULPHONAMIDE DERIVATIVES | Biotie Therapies Corp. (FI) | 2006-12-20 | — | — | EP | disclosed |
| WO-2005090298-A1 | SULPHONAMIDE DERIVATIVES | BIOTIE THERAPIES CORPORATION (FI) | 2005-09-29 | — | — | WO | disclosed |
| WO-2005090297-A1 | SULPHONAMIDE DERIVATIVES | BIOTIE THERAPIES CORPORATION (FI) | 2005-09-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080255169-A1 | 4'-Fluoro-biphenyl-3-sulfonic acid benzo[1,3]dioxol-5-ylamide, for example; for use as an alpha 2 beta 1 integrin I domain inhibitor; use as a medicament for treating thrombosis and cancer spread | NR1I2, ITGA2, ITGB2 | PTPN2 1095/4885PTPN1 1619/4885PTPN5 1697/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.